BRISTOL-MYERS SQUIBB COMPANY Equity Securities, FV-NI, Gain (Loss)
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Equity Securities, FV-NI, Gain (Loss) of $170.00 million for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiGainLoss · last filed 2020-11-05
- BRISTOL-MYERS SQUIBB COMPANY equity securities, fv-ni, gain (loss) for the quarter ending 2020-09-30 was $170.00M.
- BRISTOL-MYERS SQUIBB COMPANY equity securities, fv-ni, gain (loss) for the quarter ending 2020-06-30 was $635.00M, a 976.27% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY equity securities, fv-ni, gain (loss) for the quarter ending 2020-03-31 was -$228.00M, a 340.00% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY equity securities, fv-ni, gain (loss) for the quarter ending 2019-12-31 was $251.00M.
- BRISTOL-MYERS SQUIBB COMPANY equity securities, fv-ni, gain (loss) for fiscal 2019 was $170.00M.
- BRISTOL-MYERS SQUIBB COMPANY equity securities, fv-ni, gain (loss) for fiscal 2018 was -$530.00M.
| Period end | Equity Securities, FV-NI, Gain (Loss) 3 month | Equity Securities, FV-NI, Gain (Loss) 6 month | Equity Securities, FV-NI, Gain (Loss) 9 month | Equity Securities, FV-NI, Gain (Loss) 12 month |
|---|---|---|---|---|
| 2020-09-30 | $170.00M 10-Q · filed 2020-11-05 | $805.00M derived: sum of 2 quarters · filed 2020-11-05 | $577.00M 10-Q · filed 2020-11-05 | $828.00M derived: sum of 4 quarters · filed 2020-11-05 |
| 2020-06-30 | $635.00M 10-Q · filed 2020-08-06 | $407.00M 10-Q · filed 2020-08-06 | $658.00M derived: sum of 3 quarters · filed 2020-08-06 | $423.00M derived: sum of 4 quarters · filed 2020-11-05 |
| 2020-03-31 | -$228.00M 10-Q · filed 2020-05-07 | $23.00M derived: sum of 2 quarters · filed 2020-05-07 | -$212.00M derived: sum of 3 quarters · filed 2020-11-05 | -$153.00M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-12-31 | $251.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $16.00M derived: sum of 2 quarters · filed 2020-11-05 | $75.00M derived: sum of 3 quarters · filed 2020-11-05 | $170.00M 10-K · filed 2020-02-24 |
| 2019-09-30 | -$235.00M 10-Q · filed 2020-11-05 | -$176.00M derived: sum of 2 quarters · filed 2020-11-05 | -$81.00M 10-Q · filed 2020-11-05 | -$349.00M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $59.00M 10-Q · filed 2020-08-06 | $154.00M 10-Q · filed 2020-08-06 | -$114.00M derived: sum of 3 quarters · filed 2020-08-06 | -$17.00M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $95.00M 10-Q · filed 2020-05-07 | -$173.00M derived: sum of 2 quarters · filed 2020-05-07 | -$76.00M derived: sum of 3 quarters · filed 2020-05-07 | -$450.00M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | -$268.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | -$171.00M derived: sum of 2 quarters · filed 2020-02-24 | -$545.00M derived: sum of 3 quarters · filed 2020-02-24 | -$530.00M 10-K · filed 2020-02-24 |
| 2018-09-30 | $97.00M 10-Q · filed 2019-10-31 | -$277.00M derived: sum of 2 quarters · filed 2019-10-31 | -$262.00M 10-Q · filed 2019-10-31 | |
| 2018-06-30 | -$374.00M 10-Q · filed 2019-07-25 | -$359.00M 10-Q · filed 2019-07-25 | ||
| 2018-03-31 | $15.00M 10-Q · filed 2019-04-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |